Covaxin Phase 3 Clinical Trial
- All
- News
- Videos
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Phase 3 Data
Bharat Biotech's Covaxin is overall 77.8 per cent effective "against symptomatic COVID-19", the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
-
Covaxin Phase 2, 3 Clinical Trials For 2-18 Age Group Cleared
Covaxin trials on children from two to 18 years were cleared by the Drugs Controller General of India (DCGI) today. This is the first time in India that a Covid vaccine will be tested on children.
-
Covaxin Safe, Phase 3 Results Needed To Assess Effectiveness, Says Lancet
Covaxin, the homegrown coronavirus vaccine that was authorized for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its phase 2 results.
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial
Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, ''Covaxin''.
-
Bharat Biotech's COVID-19 Vaccine 'Covaxin' Begins Phase-3 Clinical Trial In Kolkata
West Bengal Governor Jagdeep Dhankhar today inaugurated the launch of Phase-3 regulatory trial of Covaxin at ICMR-NICED in Kolkata, lauding the country's leadership for "effectively tackling" the COVID-19 pandemic.
-
COVID-19 Vaccine Covaxin's Phase 3 Trial Begins In Gujarat Hospital
The phase-3 clinical trials of Bharat Biotech's COVID-19 vaccine began at Sola civil hospital in Gujarat's Ahmedabad city on Thursday, officials of the state-run hospital said.
-
Phase 3 Trials Of Covaxin Begin, AMU Vice Chancellor Is First Volunteer
The third phase of clinical trials for Covaxin, the coronavirus vaccine being developed by pharmaceutical firm Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has started. The Vice Chancellor of Aligarh Muslim University (AMU) registered as the first volunteer for the trails which will take place at the universit...
-
Covaxin, Bharat Biotech's Coronavirus Vaccine, Cleared For Phase 3 Trials
Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
-
Bharat Biotech Told To Submit Phase 2 Data Of Its Covid Vaccine Before Starting Phase 3: Report
Bharat Biotech, which had sought Drugs Controller General of India or DCGI's nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to first submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.
-
US Health Regulator Lifts Hold On Covaxin's Clinical Trials
The US Food and Drug Administration which has put on hold phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for jab in US, Canada
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Covaxin Overall 77.8% Effective, Claims Bharat Biotech In Phase 3 Data
Bharat Biotech's Covaxin is overall 77.8 per cent effective "against symptomatic COVID-19", the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.
-
Covaxin Phase 2, 3 Clinical Trials For 2-18 Age Group Cleared
Covaxin trials on children from two to 18 years were cleared by the Drugs Controller General of India (DCGI) today. This is the first time in India that a Covid vaccine will be tested on children.
-
Covaxin Safe, Phase 3 Results Needed To Assess Effectiveness, Says Lancet
Covaxin, the homegrown coronavirus vaccine that was authorized for use in January before full clinical trial data, has been declared "safe, immunogenic with no serious side effects" by Lancet that has published its phase 2 results.
-
Bharat Biotech Enrols Over 25,000 Volunteers For Covaxin Phase 3 Trial
Bharat Biotech has enrolled 25,800 volunteers for phase 3 clinical trials of its COVID-19 vaccine, the company said today. The maker of Covaxin is one of the two firms cleared by the government to deploy their product for mass inoculation in the country. The other is Oxford-AstraZeneca's Covishield manufactured by the Serum Institute of India.
-
Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial
Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, ''Covaxin''.
-
Bharat Biotech's COVID-19 Vaccine 'Covaxin' Begins Phase-3 Clinical Trial In Kolkata
West Bengal Governor Jagdeep Dhankhar today inaugurated the launch of Phase-3 regulatory trial of Covaxin at ICMR-NICED in Kolkata, lauding the country's leadership for "effectively tackling" the COVID-19 pandemic.
-
COVID-19 Vaccine Covaxin's Phase 3 Trial Begins In Gujarat Hospital
The phase-3 clinical trials of Bharat Biotech's COVID-19 vaccine began at Sola civil hospital in Gujarat's Ahmedabad city on Thursday, officials of the state-run hospital said.
-
Phase 3 Trials Of Covaxin Begin, AMU Vice Chancellor Is First Volunteer
The third phase of clinical trials for Covaxin, the coronavirus vaccine being developed by pharmaceutical firm Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has started. The Vice Chancellor of Aligarh Muslim University (AMU) registered as the first volunteer for the trails which will take place at the universit...
-
Covaxin, Bharat Biotech's Coronavirus Vaccine, Cleared For Phase 3 Trials
Covaxin, the coronavirus vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), has been cleared for the third phase of clinical trials.
-
Bharat Biotech Told To Submit Phase 2 Data Of Its Covid Vaccine Before Starting Phase 3: Report
Bharat Biotech, which had sought Drugs Controller General of India or DCGI's nod for conducting phase-3 clinical trials of its COVID-19 vaccine candidate, has been asked to first submit complete safety and immunogenicity data of the ongoing phase-2 trial, besides providing some clarifications, before proceeding for the next stage.
